Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announced that Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, will present at the Biotech Showcase™ Annual Conference to be held in San Francisco (CA, United States) on January 9 – 11, 2017 at the Hilton San Francisco Union Square Hotel.
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Prof. Hartmut Ehrlich will present at the Biotech Showcase™ as follows:
Date: | Tuesday, January 10, 2017 | ||||||
Time: | 10:00 am (PST) | ||||||
Track: | Room 7 (Ball room) | ||||||
Venue: | Hilton San Francisco Union Square Hotel | ||||||
333 O’Farrell Street, San Francisco, CA (United States) | |||||||
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on targeting the
immune system to eliminate viral disease. ABIVAX leverages three
technology platforms for drug discovery: an anti-viral, an immune
enhancement, and a polyclonal antibody platform. ABX464, its most
advanced compound, is currently in Phase II clinical trials for
providing a functional cure for patients with HIV/AIDS. It is a
first-in-class oral small anti-viral molecule which blocks HIV
replication through a unique mechanism of action and also has a strong
anti-inflammatory effect. In addition, ABIVAX is advancing a clinical
stage immune enhancer as well as multiple preclinical candidates against
additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several
of these compounds are planned to enter clinical development within the
next 18 months. ABIVAX is listed on Euronext compartment B (ISIN:
FR0012333284 – Mnémo: ABVX).
More information on the company is
available at www.abivax.com.
Follow us on Twitter @ABIVAX_
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104006119/en/